OTX015 (MK-8628), a novel oral BET inhibitor in early clinical development, has shown preclinical activity against a wide range of hematologic malignancies [22, 23] as well as both pediatric and adult solid tumors [24, 25]. The gene discussed is DNER; the disease is hematologic disorder.